| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology, Rabin Medical Center-Beilinson Campus, Petah Tiqva; and the Tel-Aviv University Sackler School of Medicine, Tel-Aviv, Israel.
Address correspondence and reprint requests to Dr. Ilan Ziv, Department of Neurology, Rabin Medical Center, Beilinson Campus, 49100, Petah Tiqva, Israel.
Objective: To measure fatigue quantitatively during continuous motor performance in patients with PD.
Background: Enhanced fatigue on performance of motor tasks is a very frequent and disabling complaint of PD patients, and is poorly characterized and understood. Recent evidence suggests a role for mitochondrial dysfunction in the pathogenesis of PD. Reduced exercise capacity is one of the hallmarks of systemic mitochondrial impairment.
Methods: The authors used an automated system to measure muscle fatigue during a continuous (30-second), maximal, isometric forearm flexion in 17 PD patients and 10 age-matched control subjects. A fatigue index (FI) was then calculated. Peak force (PF) was measured as an internal standard of the examination. Measurements were performed before and 2 hours after an oral dose levodopa/carbidopa (125 mg/12.5 mg).
Results: In PD patients there was a 50% increase in FI. The increased FI was often asymmetric and more pronounced on the side more affected by the disease. FI was significantly responsive to, and improved after, an oral dose of levodopa. The rate of improvement in FI induced by levodopa correlated with disease severity, as measured by the Unified Parkinson's Disease Rating Scale. No significant alterations in PF were observed.
Conclusions: Enhanced muscle fatigue should be recognized as an integral part of the spectrum of motor impairment of PD. However, our data argue for its association with a central dopamine deficiency rather than with a muscle mitochondrial abnormality.
Supported in part by the National Parkinson Foundation, Miami, FL.
Received June 19, 1998. Accepted in final form August 8, 1998.
This article has been cited by other articles:
|
|
 |
|
  C. J. Hass, M. A. Collins, and J. L. Juncos Resistance Training With Creatine Monohydrate Improves Upper-Body Strength in Patients With Parkinson Disease: A Randomized Trial Neurorehabil Neural Repair, March 1, 2007; 21(2): 107 - 115. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Chen, S. M. Zhang, M. A. Schwarzschild, M. A. Hernan, and A. Ascherio Physical activity and the risk of Parkinson disease Neurology, February 22, 2005; 64(4): 664 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A St Clair Gibson and T D Noakes Evidence for complex system integration and dynamic neural regulation of skeletal muscle recruitment during exercise in humans Br. J. Sports Med., December 1, 2004; 38(6): 797 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Garber and J. H. Friedman Effects of fatigue on physical activity and function in patients with Parkinson's disease Neurology, April 8, 2003; 60(7): 1119 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Schwid, C. A. Thornton, S. Pandya, K. L. Manzur, M. Sanjak, M. D. Petrie, M. P. McDermott, and A. D. Goodman Quantitative assessment of motor fatigue and strength in MS Neurology, September 1, 1999; 53(4): 743 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Friedman, I. Ziv, and E. Melamed Enhanced fatigue during motor performance in patients with PD Neurology, July 1, 1999; 53(2): 437 - 437. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
